lifestyle.entreprenerd.net

Author: Rezolute, Inc.

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

May 1, 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

April 21, 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

March 24, 2026